Cellular regeneration represents the leading edge of research into hair loss
Atlanta, GA (PRWeb UK) March 25, 2010
Aderans Research Institute Inc. (ARI) announced it purchased key technology assets from Regenerative Medicine Assets Limited (formerly Intercytex Group plc), a leading UK hair regeneration company. The acquisition represents a significant consolidation within the hair regeneration industry, as ARI is absorbing the scientific assets of a company that was its leading competitor.
“This acquisition is a major step forward for ARI,” said Vern Liebmann, Vice President, Operations. “Through this deal, we’ve been able to consolidate the majority of key patents and know-how in the hair regeneration field, an achievement that can accelerate our ability to deliver a commercially viable product to market. This acquisition was only possible thanks to the considerable financial support of Aderans Holdings Company, Ltd., of Japan.”
The purchase includes assets related to the ICX-TRC product that Regenerative Medicine Assets Limited had been developing. ICX-TRC is an autologous hair regeneration therapy for the treatment of male pattern baldness and female diffuse alopecia.
The deal comes as ARI is expanding its Phase 2 clinical study of cell-based hair regeneration, in which it recently treated the trial’s 100th subject. “We’ve acquired important proprietary knowledge that includes Intercytex’s clinical efforts to date,” noted Ken Washenik, MD PhD, Executive Vice President. “This information should substantially augment our ongoing efforts to produce a cell-based treatment for hair loss.”
“Cellular regeneration represents the leading edge of research into hair loss,” said Kurt Stenn, MD, Vice President and Chief Scientific Officer. “Combining the knowledge stores of two of the leading companies in this field is a major step forward in our efforts to pioneer a process of cellular hair regeneration that can deliver enhanced hair growth to millions of people around the world.”
About Aderans Research
Aderans Research is a pioneer in the research and development of safe, effective cell engineered products for hair regeneration. With offices in Atlanta and Philadelphia, Aderans Research Institute is a subsidiary of Aderans Holdings Company, Ltd., the world’s largest wig manufacturer, and an affiliate of Bosley, a global leader in medical hair restoration.
More information on ARI’s study outcomes will be released as studies unfold. To see ARI’s latest clinical updates, please visit http://aderansresearch.com/ari_clinicalupdates.html
Additional information on ARI can be found at http://www.aderansresearch.com.
Learn more about Aderans Holdings Company, Ltd. at http://www.aderans.co.jp/e/company/